Barrett J C
Laboratory of Molecular Carcinogenesis, National Institute of Environmental Health Sciences, Research Triangle Park, NC.
IARC Sci Publ. 1992(116):115-34.
Mutational mechanisms can be proposed for most, if not all, known human carcinogens. Many of these are electrophilic or metabolically activated to reactive molecules which can alter DNA, causing genetic damage and different types of mutations. Even some human carcinogens previously proposed to be nongenotoxic (e.g., hormones and asbestos) exhibit mutational activity in assays for chromosomal mutations. Since such chemicals are usually inactive in the Salmonella assay and other assays for gene mutation, more emphasis has been placed on their nonmutational mechanisms. Clear evidence exists that these carcinogens can alter gene expression and stimulate cell proliferation by epigenetic mechanisms. Such properties are undoubtedly important in their carcinogenic activity. Although they are less well studied, DNA reactive, genotoxic carcinogens also alter gene expression and increase cell turnover by epigenetic mechanisms. These findings are consistent with the current understanding of the molecular basis of multistep carcinogenesis. Most common human cancers evolve as the result of multiple mutational events. The molecular basis of these mutations is varied, and they include point mutations, deletion mutations, chromosomal rearrangements, gene amplification and chromosomal losses and gains. Therefore, different mutational activities of carcinogens can influence the carcinogenic process at different steps. Influences on gene expression and cell proliferation are also important in allowing clonal expansion of preneoplastic cells and in disrupting the suppressive effects of surrounding normal cells on preneoplastic cells (Dotto et al., 1988). The mechanisms of action of human carcinogens, and very probably many rodent carcinogens, include both genetic and epigenetic processes. Carcinogenesis is a multistep, multigenic, multicausal process (Barrett, 1987b), so both epigenetic and genetic factors are probably important.(ABSTRACT TRUNCATED AT 250 WORDS)
对于大多数(即便不是全部)已知的人类致癌物,都可以提出其突变机制。其中许多致癌物具有亲电性,或者经代谢激活成为能改变DNA的反应性分子,从而导致基因损伤和不同类型的突变。甚至一些先前被认为是非基因毒性的人类致癌物(如激素和石棉),在染色体突变检测中也表现出突变活性。由于这类化学物质在沙门氏菌检测和其他基因突变检测中通常无活性,因此人们更加关注它们的非突变机制。有明确证据表明,这些致癌物可通过表观遗传机制改变基因表达并刺激细胞增殖。这类特性在其致癌活性中无疑很重要。尽管对DNA反应性、基因毒性致癌物的研究较少,但它们也通过表观遗传机制改变基因表达并增加细胞更新。这些发现与当前对多步骤致癌作用分子基础的理解一致。大多数常见的人类癌症是多种突变事件的结果。这些突变的分子基础各不相同,包括点突变、缺失突变、染色体重排、基因扩增以及染色体的丢失和增加。因此,致癌物的不同突变活性可在不同步骤影响致癌过程。对基因表达和细胞增殖的影响在允许肿瘤前体细胞的克隆扩增以及破坏周围正常细胞对肿瘤前体细胞的抑制作用方面也很重要(多托等人,1988年)。人类致癌物以及很可能许多啮齿动物致癌物的作用机制包括遗传和表观遗传过程。致癌作用是一个多步骤、多基因、多因素的过程(巴雷特,1987b),所以表观遗传和遗传因素可能都很重要。(摘要截取自250词)